Evaluation of prognostic factors for secondary cytoreductive surgery in Chinese patients with recurrent epithelial ovarian carcinoma.
暂无分享,去创建一个
Wei Zhang | P. Wei | Xue-lian Du | Yongchun Cui | Ling Li | X. Sheng | Zhihu Zhang | Xiuxian Li | Guirong Hu
[1] G. Scambia,et al. Secondary cytoreductive surgery in patients with isolated platinum-resistant recurrent ovarian cancer: a retrospective analysis. , 2014, Gynecologic oncology.
[2] M. Moreno-Eutimio,et al. Management of recurrent epithelial ovarian cancer. , 2014, Gland surgery.
[3] M. Del Pilar Estevez Diz,et al. Neoadjuvant chemotherapy with six cycles of carboplatin and paclitaxel in advanced ovarian cancer patients unsuitable for primary surgery: Safety and effectiveness. , 2014, Gynecologic oncology.
[4] G. Scambia,et al. Minimally invasive secondary cytoreduction plus HIPEC for recurrent ovarian cancer: a case series. , 2014, Gynecologic oncology.
[5] Xiaoxiang Chen,et al. Secondary cytoreduction surgery improves prognosis in platinum-sensitive recurrent ovarian cancer , 2013, Journal of experimental & clinical cancer research : CR.
[6] J. Ledermann,et al. Optimal first-line treatment in ovarian cancer. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.
[7] J. Berek,et al. Predictors of survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery based on the pooled analysis of an international collaborative cohort , 2011, British Journal of Cancer.
[8] J. Sehouli,et al. Prognostic significance of CA-125 in the management of patients with recurrent epithelial ovarian carcinoma selected for secondary cytoreduction. , 2009, Anticancer research.
[9] R. Sayer,et al. Cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma. , 2007, Gynecologic oncology.
[10] R. Bristow,et al. Secondary cytoreductive surgery for localized recurrent epithelial ovarian cancer: Analysis of prognostic factors and survival outcome , 2006 .
[11] E. Venkatraman,et al. Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum‐sensitive epithelial ovarian carcinoma , 2006, Cancer.
[12] R. Bristow,et al. Secondary cytoreduction for patients with recurrent ovarian cancer , 2005, Current oncology reports.
[13] Y. Taketani,et al. Secondary cytoreductive surgery for recurrent epithelial ovarian carcinoma: proposal for patients selection , 2005, British Journal of Cancer.
[14] I. Christensen,et al. Surgical cytoreduction in recurrent ovarian carcinoma in patients with complete response to paclitaxel-platinum. , 2005, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[15] N. Teng,et al. Secondary cytoreductive surgery for patients with relapsed epithelial ovarian carcinoma: Who benefits? , 2004, Cancer.
[16] R. Zang,et al. Surgery and salvage chemotherapy for Chinese women with recurrent advanced epithelial ovarian carcinoma: A retrospective case-control study , 2003, International Journal of Gynecologic Cancer.
[17] A. Carbone,et al. Secondary cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma. , 2001, Gynecologic oncology.
[18] J. Wolf,et al. Secondary cytoreductive surgery for localized intra-abdominal recurrences in epithelial ovarian cancer. , 2001, Gynecologic oncology.
[19] A. Jemal,et al. Cancer statistics, 2014 , 2014, CA: a cancer journal for clinicians.
[20] G. Gardner,et al. Current and future directions of clinical trials for ovarian cancer. , 2011, Cancer control : journal of the Moffitt Cancer Center.
[21] D. Chi,et al. Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis. , 2009, Gynecologic oncology.
[22] N. Spirtos,et al. The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma , 2000, Cancer.